ASTRAZENECA PLC (AZN) Form 6-K — Sep 23, 2026
AstraZeneca's fixed-dose triple-combination therapy Trixeo Aerosphere (budesonide/glycopyrronium/formoterol) has been approved by the European Commission as a maintenance treatment for asthma in patients 12 years and older inadequately controlled on medium-dose ICS/LABA therapy. Trixeo is the first and only triple-combination therapy approved in the EU for asthma independent of exacerbation history, based on positive results from the KALOS and LOGOS Phase III trials involving approximately 4,300 patients, which showed statistically significant lung function improvements and reduced severe exacerbation rates versus ICS/LABA dual therapy.
Key figures
- Eu asthma patients
- nearly 43 million
- Patients treated 2025
- more than 6.8 million
- Global asthma prevalence
- 363 million people worldwide
- New diagnoses annually eu
- about 4 million
- Countries approved for copd
- more than 90
- Kalos logos randomized patients
- approximately 4,300
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.